Showing results for 
Search instead for 
Did you mean: 

Mining the malignant ascites proteome for pancreatic cancer biomarkers

Reputable Mentor II
Reputable Mentor II
Kosanam H, Makawita S, Judd B, Newman A, Diamandis EP.
Proteomics. 2011 Dec;11(23):4551-8.
Pancreatic cancer (PC) is one of the most lethal malignancies and disease-specific biomarkers are desperately needed for better diagnosis, prognosis, monitoring treatment efficacy and for accelerating the development of novel targeted therapeutics. Being an advanced stage manifestation and a proximal fluid in contact with cancer tissues, the ascitic fluid presents itself as a promising rich source of biomarkers. Herein, we present a comprehensive proteomic analysis of pancreatic ascitic fluid. To fractionate the complex ascites proteome, we adopted a multi-dimensional chromatographic approach that included size-exclusion, ion-exchange and lectin-affinity chromatographic techniques. Our detailed proteomic analysis with high-resolution Orbitrap® mass spectrometer resulted in the identification of 816 proteins. We followed rigorous filtering criteria that consisted of PC-specific information obtained from three publicly available databases (Oncomine, Protein Atlas and Unigene) to segregate 20 putative biomarker candidates for future validation. Since these proteins are of membranous and extra-cellular origin, most are glycosylated, and many of them are over-expressed in cancer tissues, the probability of these proteins entering the peripheral blood circulation is high. Their validation as serological PC biomarkers in the future is highly warranted.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Version history
Last update:
‎11-09-2021 01:41 AM
Updated by: